Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Department of Pathology, Duke University Medical Center, Durham, North Carolina.
Clin Cancer Res. 2018 Sep 1;24(17):4175-4186. doi: 10.1158/1078-0432.CCR-17-1846. Epub 2018 Feb 7.
T-cell dysfunction is a hallmark of glioblastoma (GBM). Although anergy and tolerance have been well characterized, T-cell exhaustion remains relatively unexplored. Exhaustion, characterized in part by the upregulation of multiple immune checkpoints, is a known contributor to failures amid immune checkpoint blockade, a strategy that has lacked success thus far in GBM. This study is among the first to examine, and credential as , exhaustion among T cells infiltrating human and murine GBM. Tumor-infiltrating and peripheral blood lymphocytes (TILs and PBLs) were isolated from patients with GBM. Levels of exhaustion-associated inhibitory receptors and poststimulation levels of the cytokines IFNγ, TNFα, and IL2 were assessed by flow cytometry. T-cell receptor Vβ chain expansion was also assessed in TILs and PBLs. Similar analysis was extended to TILs isolated from intracranial and subcutaneous immunocompetent murine models of glioma, breast, lung, and melanoma cancers. Our data reveal that GBM elicits a particularly severe T-cell exhaustion signature among infiltrating T cells characterized by: (1) prominent upregulation of multiple immune checkpoints; (2) stereotyped T-cell transcriptional programs matching classical virus-induced exhaustion; and (3) notable T-cell hyporesponsiveness in tumor-specific T cells. Exhaustion signatures differ predictably with tumor identity, but remain stable across manipulated tumor locations. Distinct cancers possess similarly distinct mechanisms for exhausting T cells. The poor TIL function and severe exhaustion observed in GBM highlight the need to better understand this tumor-imposed mode of T-cell dysfunction in order to formulate effective immunotherapeutic strategies targeting GBM. .
T 细胞功能障碍是胶质母细胞瘤(GBM)的标志。虽然已充分研究了无反应性和耐受性,但 T 细胞衰竭仍相对未知。衰竭的特点部分是多种免疫检查点的上调,这是免疫检查点阻断失败的已知原因,而这种策略迄今为止在 GBM 中缺乏成功。这项研究是首批研究之一,研究了浸润性人类和鼠 GBM 的 T 细胞衰竭,并为其提供了依据。从 GBM 患者中分离肿瘤浸润和外周血淋巴细胞(TIL 和 PBL)。通过流式细胞术评估衰竭相关抑制性受体的水平和刺激后 IFNγ、TNFα 和 IL2 细胞因子的水平。还评估了 TIL 和 PBL 中的 T 细胞受体 Vβ 链扩张。类似的分析扩展到从小鼠脑内和皮下免疫活性胶质瘤、乳腺癌、肺癌和黑色素瘤癌症模型中分离的 TIL。我们的数据表明,GBM 引发了浸润性 T 细胞中特别严重的 T 细胞衰竭特征,其特征为:(1)多个免疫检查点的显著上调;(2)与经典病毒诱导的衰竭相匹配的刻板 T 细胞转录程序;(3)肿瘤特异性 T 细胞的明显 T 细胞低反应性。衰竭特征与肿瘤特征可预测地不同,但在经过操作的肿瘤位置之间保持稳定。不同的癌症具有相似的耗尽 T 细胞的机制。在 GBM 中观察到的 TIL 功能差和严重衰竭突出表明需要更好地了解这种肿瘤强加的 T 细胞功能障碍模式,以便制定针对 GBM 的有效免疫治疗策略。